The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study-Reference-Cited by-同舟云学术

The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study

Published:2021-05-25 Issue:12 Volume:48 Page:4067-4076
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Ahmadzadehfar Hojjat^ORCID,Matern Ralf,Baum Richard P.,Seifert Robert,Kessel Katharina,Bögemann Martin,Kratochwil Clemens,Rathke Hendrik,Ilhan Harun,Svirydenka Hanna,Sathekge Mike,Kabasakal Levent,Yordanova Anna,Garcia-Perez Francisco Osvaldo,Kairemo Kalevi,Maharaj Masha,Paez Diana,Virgolini Irene,Rahbar Kambiz

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00259-021-05383-3.pdf

Reference28 articles.

1. Ahmadzadehfar H, Rahbar K, Baum RP, Seifert R, Kessel K, Bogemann M, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-04797-9.

2. Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kurpig S, Eppard E, et al. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [(177)Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging. 2017;44:1448–54. https://doi.org/10.1007/s00259-017-3716-2.

3. Ahmadzadehfar H, Zimbelmann S, Yordanova A, Fimmers R, Kurpig S, Eppard E, et al. Radioligand therapy of metastatic prostate cancer using (177)Lu-PSMA-617 after radiation exposure to (223)Ra-dichloride. Oncotarget. 2017;8:55567–74. https://doi.org/10.18632/oncotarget.15698.

4. Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP. Clinical outcomes of (177)Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy. J Nucl Med. 2019;60:955–62. https://doi.org/10.2967/jnumed.118.216820.

5. Brauer A, Grubert LS, Roll W, Schrader AJ, Schafers M, Bogemann M, et al. (177)Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1663–70. https://doi.org/10.1007/s00259-017-3751-z.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PSMA-based therapeutics for prostate cancer;Expert Opinion on Pharmacotherapy;2024-07-02

2. Prostate Cancer Theranostics With 177Lu-PSMA;Seminars in Nuclear Medicine;2024-07

3. Short-Term Biological Toxicity Prediction of [¹⁷⁷Lu]Lutetium-Oxodotreotide: An Original Retrospective Analysis;Cancer Biotherapy and Radiopharmaceuticals;2024-06-01

4. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study;The Lancet Oncology;2024-02

5. Targeted alpha therapy: a new tool for advanced prostate cancer;The Lancet Oncology;2024-02